Publications in collaboration with researchers from Hospital de Cabueñes (11)

2023

  1. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2015

  1. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 17, Núm. 11, pp. 862-869

2014

  1. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

2011

  1. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

  2. Management of patients with metastatic breast cancer

    Advances in Therapy, Vol. 28, Núm. SUPPL. 6, pp. 50-65

2010

  1. Novel therapeutic approaches to the treatment of metastatic breast cancer

    Cancer Treatment Reviews, Vol. 36, Núm. 1, pp. 33-42

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814